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BACKGROUND: Lowering of atherogenic lipoproteins, including low-density 
lipoprotein cholesterol (LDL-C), reduces the risk of ischemic stroke. However, 
concerns have been raised about very low LDL-C levels and a potential increased 
risk of hemorrhagic stroke. ODYSSEY OUTCOMES compared the PCSK9 inhibitor 
alirocumab with placebo in 18 924 patients with recent acute coronary syndrome 
and elevated atherogenic lipoproteins, despite intensive statin therapy, targeting 
LDL-C levels of 25 to 50 mg/dL and avoiding sustained LDL-C <15 mg/dL. This 
prespecified analysis was designed to assess the effect of alirocumab on ischemic 
and hemorrhagic stroke. We hypothesized that for patients treated with alirocumab 
there would be a reduction in risk of ischemic stroke without increasing hemorrhagic 
stroke, irrespective of baseline LDL-C and of history of cerebrovascular disease.
METHODS: Patients were randomized to alirocumab or placebo 1 to 12 months 
after acute coronary syndrome. The risk of nonfatal or fatal ischemic or hemorrhagic 
stroke was evaluated, stratified by baseline LDL-C concentration and history of 
cerebrovascular disease. A potential association of very low achieved LDL-C with 
alirocumab treatment at month 4 and subsequent hemorrhagic stroke was assessed.
RESULTS: Median follow-up was 2.8 years. In total, 263 ischemic and 33 
hemorrhagic strokes occurred. Alirocumab reduced the risk of any stroke (HR, 
0.72 [95% CI, 0.57−0.91]) and ischemic stroke (HR, 0.73 [95% CI, 0.57−0.93]) 
without increasing hemorrhagic stroke (HR, 0.83 [95% CI, 0.42−1.65]). In total, 
7164 (37.9%), 6128 (32.4%), and 5629 (29.7%) patients had a baseline LDL-C 
of <80, 80 to 100, and >100 mg/dL, respectively. The treatment effect on stroke 
appeared numerically greater for patients with higher baseline LDL-C, but there 
was no formal evidence of heterogeneity (Pinteraction=0.31). The effect of alirocumab 
on stroke was similar among 944 patients (5.0%) with a history of previous 
cerebrovascular disease and among those without a history of cerebrovascular 
disease (Pinteraction=0.37). There was no apparent adverse relation between lower 
achieved LDL-C and incidence of hemorrhagic stroke in the alirocumab group.
CONCLUSIONS: In patients with recent acute coronary syndrome and 
dyslipidemia despite intensive statin therapy, alirocumab decreased the risk of 
stroke, irrespective of baseline LDL-C and history of cerebrovascular disease, over 
a median follow-up of 2.8 years. Furthermore, risk of hemorrhagic stroke did not 
depend on achieved LDL-C levels within the alirocumab group.
CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. 
Unique identifier: NCT01663402.
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Lowering of atherogenic lipoproteins with statin treatment reduces the risk of first or recurrent stroke,1–3 and the benefit has been shown by the 
Cholesterol Treatment  Trialist meta-analysis to be di-
rectly proportional to the degree of absolute lowering 
of low-density lipoprotein cholesterol (LDL-C).4 Accord-
ingly, international guidelines recommend statin treat-
ment for patients at high cardiovascular risk or with 
established cardiovascular disease with or without a 
history of cerebrovascular disease, to prevent major car-
diovascular events, including ischemic stroke.5,6
Although some data have raised a potential associa-
tion of very low LDL-C levels and risk of hemorrhagic 
stroke,7,8 the decrease in ischemic stroke outweighed 
the potential increase in hemorrhagic stroke.4,9 The 
advent of inhibitors of PCSK9 (proprotein convertase 
subtilisin−kexin type 9) provided an opportunity to 
lower LDL-C to levels not previously achievable in most 
patients with statins and/or ezetimibe. Two large car-
diovascular outcomes trials have compared the effect 
of a fully human PCSK9 inhibitor with placebo on the 
risk of stroke in patients with atherosclerotic cardio-
vascular disease and elevated atherogenic lipoproteins 
despite background statin treatment.10,11 In both trials, 
treatment with the PCSK9 inhibitor lowered LDL-C by 
more than 50% below the statin-treated baseline. The 
FOURIER trial (Further Cardiovascular Outcomes Re-
search With PCSK9 Inhibition in Patients With Elevated 
Risk)10 compared evolocumab with placebo in patients 
with established, stable, atherosclerotic cardiovascular 
disease. Evolocumab treatment reduced the risk of isch-
emic stroke without a significant effect on hemorrhagic 
stroke. The ODYSSEY OUTCOMES trial (Evaluation of 
Cardiovascular Outcomes After an Acute Coronary 
Syndrome During Treatment With Alirocumab)11 com-
pared alirocumab with placebo in 18 924 patients with 
recent acute coronary syndrome (ACS) and showed a 
reduction in major adverse cardiovascular events with 
alirocumab compared with placebo. This prespecified 
analysis was designed to assess the effect of alirocum-
ab on ischemic and hemorrhagic stroke. We hypoth-
esized that for patients treated with alirocumab, there 
would be a reduction in risk of ischemic stroke without 
increasing hemorrhagic stroke, irrespective of baseline 
LDL-C and of history of cerebrovascular disease.
METHODS
The data that support the findings of this study are available 
from the corresponding author upon reasonable request.
Details of the study design12 and primary efficacy and safety 
results11 have been published. In brief, ODYSSEY OUTCOMES 
was a multicenter, double-blind, placebo-controlled trial in 
18 924 patients at least 40 years of age who provided writ-
ten informed consent and had been hospitalized with an ACS 
(defined as myocardial infarction or unstable angina) 1 to 12 
months before randomization. Qualifying patients had a level 
of LDL-C ≥70 mg/dL (1.81 mmol/L), or non−high-density lipo-
protein cholesterol (non–HDL-C) ≥100 mg/dL (2.59 mmol/L), 
or apolipoprotein B ≥80 mg/dL (0.8 mmol/L), measured after 
a minimum of 2 weeks of stable treatment with atorvas-
tatin 40 to 80 mg daily, rosuvastatin 20 to 40 mg daily, or 
the maximum tolerated dose of either statin (including no 
statin in case of documented intolerance). All sites obtained 
institutional review board approval as per local and national 
guidelines.
Patients were randomly assigned in a 1:1 ratio stratified 
by country to receive treatment with alirocumab 75 mg sub-
cutaneously every 2 weeks or matching placebo. In case of 
a persistent LDL-C ≥50 mg/dL, the dose of alirocumab was 
up-titrated to 150 mg/dL. When 2 consecutive measurements 
of LDL-C <25 mg/dL were identified, the alirocumab dose 
was reduced to 75 mg (if measurements were made on the 
150-mg dose), and safety was monitored by an independent 
physician blinded to treatment allocation. In case of two con-
secutive measurements of LDL-C <15 mg/dL on alirocumab 
75 mg, alirocumab was discontinued with blinded substitu-
tion of placebo for the remainder of the trial. The protocol did 
not specify any change to the background statin dose.
Patients were compared based on three prespecified cat-
egories of baseline LDL-C (ie, <80 mg/dL, 80 to 100 mg/
dL, ≥100 mg/dL). We compared the effect of alirocumab on 
stroke among patients with or without a history of cerebro-
vascular disease, defined as a history of carotid endarterec-
tomy, carotid stenting, previous stroke, or transient ischemic 
attack. A multivariable prediction model of stroke risk was 
performed. Last, a subgroup analysis was performed based on 
the treat-to-target design of the trial, where patients assigned 
Clinical Perspective
What Is New?
• In a randomized, double-blind trial in 18 924 
patients with acute coronary syndrome and ele-
vated atherogenic lipoproteins despite intensive 
statin treatment, PCSK9 (proprotein convertase 
subtilisin−kexin type 9) inhibition with alirocumab 
significantly decreased the risk of ischemic stroke, 
without increasing hemorrhagic stroke.
• This effect did not depend on baseline low-density 
lipoprotein cholesterol or history of cerebrovascular 
disease.
• Furthermore, the present findings indicate that risk 
of hemorrhagic stroke did not depend on achieved 
low-density lipoprotein cholesterol levels in the ali-
rocumab group.
What Are the Clinical Implications?
• Alirocumab added to intensive statin therapy pro-
vides an opportunity to lower low-density lipopro-
tein cholesterol to levels not previously achievable 
in most patients with statins and/or ezetimibe.
• Lowering of low-density lipoprotein cholesterol to 
very low levels reduces the risk of ischemic stroke 
without increasing hemorrhagic stroke.
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to alirocumab treatment were classified in the following cat-
egories on the basis of their achieved LDL-C value at month 
4: below target range (<25 mg/dL), within target range (25 to 
<50 mg/dL), above target range (50 to <70 mg/dL), and very 
above target range (≥70 mg/dL). In this analysis, the incidence 
of hemorrhagic stroke after month 4 was summarized among 
patients in each of these achieved LDL-C categories.
End Points
End points were classified as fatal or nonfatal ischemic or 
hemorrhagic stroke, adjudicated by physicians who were 
unaware of the study treatment group assignments. As part 
of the original analysis conventions, an ischemic or unclassi-
fied stroke that was followed by a death within 30 days with 
a cause of ischemic or undetermined stroke was considered a 
fatal ischemic stroke, with an event date of the initial event. 
For the purposes of the current report, this convention was 
applied for hemorrhagic strokes (ie, a hemorrhagic stroke that 
was followed by a death within 30 days was considered a fatal 
hemorrhagic stroke, with an event date of the initial event). In 
addition, 9 nonfatal strokes with an unclassified cause were 
grouped with nonfatal ischemic strokes, as prespecified in the 
design of the study.
Statistical Considerations
Analyses of clinical outcomes and LDL-C levels were per-
formed according to the intention-to-treat principle, including 
all patients, events, and measurements from randomization to 
the study end date (November 11, 2017). Hazard ratios (HR) 
and 95% CIs were estimated by Cox proportional hazards 
models, stratified by geographic region; P values were deter-
mined using stratified log-rank tests. End point rates were 
based on observed incidences. The treatment proportional 
hazards assumption for each type of stroke (any, ischemic, 
hemorrhagic) was assessed by a Kolmogorov-type supremum 
test. A multivariable model was performed to predict all-cause 
stroke with stepwise selection, using P=0.05 for entry or exit. 
Prespecified candidate variables were age category, sex, race, 
region, index event, lipid-lowering therapy at randomization, 
LDL-C, HDL-C, lipoprotein(a), body mass index, systolic blood 
pressure, glomerular filtration rate, diabetes, hypertension, 
myocardial infarction, cerebrovascular disease, malignant dis-
ease, percutaneous coronary intervention, chronic obstructive 
pulmonary disease, coronary artery bypass grafting, periph-
eral artery disease, chronic heart failure, venous thromboem-
bolism, atrial fibrillation, current smoker, revascularization for 
index event, oral adenosine diphosphate receptor antagonist, 
oral anticoagulant, and alirocumab treatment. Relationships 
between categories of achieved month-4 LDL-C and subse-
quent hemorrhagic stroke in the alirocumab group were sum-
marized by descriptive statistics. Analyses were performed in 
SAS 9.4 and S+ 8.2.
RESULTS
Of 18 924 randomized patients, 9462 were assigned to 
the alirocumab group and 9462 to the placebo group, 
with a median (quartile 1, quartile 3) follow-up of 2.8 
(2.3, 3.4) years. There were no major  differences in 
baseline characteristics between the alirocumab group 
and the placebo group.11 At baseline, there were 944 
patients (5.0%) with a history of cerebrovascular dis-
ease and 17 980 (95.0%) without a history of cerebro-
vascular disease.
Table  1 summarizes the baseline characteristics of 
patients with or without a history of cerebrovascular 
disease. Compared with patients without a history of 
cerebrovascular disease, those with cerebrovascular 
disease were older (median age, 63 vs 58 years) and 
included more women (31.9% vs 24.8%). Of all pa-
tients with cerebrovascular disease, 611 (64.7%) had a 
history of stroke. Furthermore, compared with patients 
without a history of cerebrovascular disease, those with 
cerebrovascular disease had a higher systolic blood 
pressure and more often had comorbidities, including 
a history of diabetes, hypertension, myocardial infarc-
tion, atrial fibrillation, peripheral artery disease, venous 
thromboembolism, chronic obstructive pulmonary dis-
ease, heart failure, malignant disease, percutaneous 
coronary intervention, coronary artery bypass grafting, 
and a glomerular filtration rate <60 mL/min/1.73m2). 
Median (quartile 1, quartile 3) baseline LDL-C was 91 
(76 110) mg/dL in patients with cerebrovascular dis-
ease versus 86 (73 104) mg/dL in those without cere-
brovascular disease.
The Kaplan-Meier curves for any stroke, ischemic 
stroke, and hemorrhagic stroke are shown in Figure 1. 
In total, 263 ischemic strokes and 33 hemorrhagic 
strokes occurred. Of the 33 hemorrhagic strokes, 25 
occurred in the safety population during the treatment-
emergent adverse event reporting period,11 and 8 were 
captured in the intention-to-treat analysis. Alirocumab 
reduced the risk of any stroke (HR, 0.72 [95% CI, 0.57–
0.91]) and ischemic stroke (HR, 0.73 [95% CI, 0.57–
0.93]) without increasing hemorrhagic stroke (HR, 0.83 
[95% CI, 0.42–1.65]). There was no evidence of non-
proportionality in the treatment effects (supremum test 
P=0.56, 0.35, and 0.47 for any, ischemic, and hemor-
rhagic, respectively).
Figure 2 shows the HRs for stroke by baseline LDL-
C category and history of cerebrovascular disease. In 
total, 7164 (37.9%) patients had a baseline LDL-C 
<80 mg/dL, 6128 (32.4%) had a value of 80 to 100 
mg/dL, and 5629 (29.7%) had a value >100 mg/dL. 
The treatment effect appeared numerically greater 
for patients with higher baseline LDL-C, but there 
was no formal evidence of treatment effect hetero-
geneity (Pinteraction=0.31). An exploratory analysis was 
performed in which baseline LDL-C was categorized 
dichotomously (<100 mg/dL and ≥100 mg/dL), which 
also found no formal evidence of treatment effect 
heterogeneity (Pinteraction=0.18). Similarly, the effect of 
alirocumab on stroke appeared consistent regardless 
of the presence (n=944 patients [5.0%]) or absence of 
a history of cerebrovascular disease, (Pinteraction=0.37).
Jukema et al Effect of Alirocumab on Stroke After ACS
Circulation. 2019;140:2054–2062. DOI: 10.1161/CIRCULATIONAHA.119.043826 December 17/24, 2019 2057
ORIGINAL RESEARCH 
ARTICLE
The multivariable baseline predictors of any stroke 
are shown in Table 2. History of cerebrovascular disease 
was the strongest predictor, with a HR of 2.469 (95% CI, 
1.792–3.401; P<0.0001). In addition, glomerular filtra-
tion rate <60 mL/min/1.73 m2), diabetes, heart failure, 
myocardial infarction, oral anticoagulants, current smok-
ing and peripheral artery disease, and increasing age, sys-
tolic blood pressure, and LDL-C were associated with an 
increased risk of all-cause stroke (all P<0.05). Alirocumab 
had the strongest negative association with stroke (HR, 
0.712 [95% CI, 0.564–0.898]; P=0.0041). Per 1-mg/dL 
increment, HDL-C also had a negative association with 
stroke (HR, 0.989 [95% CI, 0.978–1.000]; P=0.0476).
Achieved LDL-C at month 4 by treatment group is 
shown in Figure 3. Among the 9462 alirocumab-assigned 
patients, 3397 (35.9%) achieved LDL-C concentrations 











  Age, y 63 (57, 70) 58 (52, 65) <0.001
  Women 301 (31.9) 4461 (24.8) <0.001
Race
  White 754 (79.9) 14 270 (79.4) 0.004
  Asian 107 (11.3) 2391 (13.3)  
  Black 39 (4.1) 434 (2.4)  
  Other 44 (4.7) 885 (4.9)  
Geographic region
  Western Europe 171 (18.1) 4004 (22.3) <0.001
  Eastern Europe 255 (27.0) 5182 (28.8)  
  North America 224 (23.7) 2647 (14.7)  
  South America 111 (11.8) 2477 (13.8)  
  Asia 101 (10.7) 2192 (12.2)  
  Rest of world 82 (8.7) 1478 (8.2)  
Risk factors/medical history
  Body mass index, kg/m2 28.1 (25.2, 31.3) 27.9 (25.2, 31.1) 0.24
  Systolic blood pressure, 
mm Hg
130 (120, 141) 126 (117, 137) <0.001
  Diabetes 414 (43.9) 5030 (28.0) <0.001
  Current smoking 190 (20.1) 4370 (24.3) 0.003
  Hypertension 830 (87.9) 11 419 (63.5) <0.001
  Myocardial infarction 288 (30.5) 3351 (18.6) <0.001
  Stroke 611 (64.7) 0 <0.001
  Atrial fibrillation 54 (5.7) 357 (2.0) <0.001
  Peripheral artery disease 149 (15.8) 610 (3.4) <0.001
  Venous 
thromboembolism
17 (1.8) 182 (1.0) 0.021
  Chronic obstructive 
pulmonary disease
69 (7.3) 677 (3.8) <0.001
  Heart failure 232 (24.6) 2583 (14.4) <0.001
  Malignant disease 46 (4.9) 486 (2.7) <0.001
  Percutaneous coronary 
intervention
277 (29.3) 2964 (16.5) <0.001
  Coronary artery bypass 
graft
139 (14.7) 908 (5.1) <0.001
  Glomerular filtration rate 
<60 mL/min/1.73 m2)
265 (28.1) 2274 (12.7) <0.001
Index event
  Time from acute 
coronary syndrome to 
randomization, months
2.8 (1.8, 4.7) 2.6 (1.7, 4.3) 0.04
Acute coronary syndrome type
  Non−ST-segment 
elevation myocardial 
infarction
533 (56.6) 8642 (48.1) <0.001
  ST-segment elevation 
myocardial infarction
261 (27.7) 6275 (35.0)  
(Continued )
  Unstable angina 148 (15.7) 3034 (16.9)  
  Revascularization 645 (68.3) 13 032 (72.5) 0.005
Medications
  Aspirin 875 (92.7) 17 211 (95.7) <0.001
  High-intensity statin 800 (84.7) 16 011 (89.0) <0.001
  Oral adenosine 
diphosphate receptor 
antagonist
922 (97.7) 17 782 (98.9) 0.001
  Specific oral 
anticoagulant
101 (10.7) 680 (3.8) <0.001
  ACE inhibitor or ARB 778 (82.4) 13 938 (77.5) <0.001
  β-blocker 796 (84.3) 15 199 (84.5) 0.86
Lipoproteins, mg/dL
  Lipoprotein(a) 22.4 (7.6, 62.1) 21.2 (6.9, 57.5) 0.09
  HDL-C 43 (36, 51) 42 (36, 50) 0.20
  LDL-C 91 (76, 110) 86 (73, 104) <0.001
  Non−HDL-C 121 (104, 144) 115 (99, 137) <0.001
  Triglycerides 136 (97, 190) 129 (94, 182) 0.002
  Total cholesterol 166 (148, 190) 159 (142, 182) <0.001
  Apolipoprotein B 83 (72, 96) 79 (69, 93) <0.001
  C-reactive protein, 
mg/dL
0.22 (0.10, 0.48) 0.16 (0.08, 0.38) <0.001
  Glycated hemoglobin 
A1c, %
6.1 (5.7, 7.0) 5.8 (5.5, 6.3) <0.001
  Switched to blinded 
placebo after 
randomization
27 (2.9) 703 (3.9) 0.10
Data presented as n (%), median (quartile 1, quartile 3). A Wilcoxon rank-
sum test was used to compare means for continuous variables and chi-square 
tests for categorical variables.  To convert the values for cholesterol to mmol/L, 
multiply by 0.02586. To convert the values for triglycerides to mmol/L, multiply 
by 0.01129. ACE indicates angiotensin-converting enzyme inhibitor; ARB, 
angiotensin receptor blocker; HDL-C, high-density lipoprotein cholesterol; and 
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at month 4 <25 mg/dL, 3749 (39.6%) achieved 25 to 
<50 mg/dL, 1087 (11.5%) achieved 50 to <70 mg/dL, 
and 1169 (12.4%) achieved ≥70 mg/dL. Table 3 shows 
the incidence of hemorrhagic stroke by ordered category 
of month 4 achieved LDL-C in the alirocumab group. 
There was no apparent adverse relation between lower 
achieved LDL-C and incidence of hemorrhagic stroke, 
with a numerically lower proportion of patients in the 
lowest categories of achieved LDL-C (ie, <50 mg/dL) ex-
periencing this outcome.
DISCUSSION
In patients with recent ACS and dyslipidemia despite in-
tensive statin therapy, alirocumab decreased the risk of 
ischemic stroke without increasing hemorrhagic stroke. 
Furthermore, risk of hemorrhagic stroke did not de-
pend on achieved LDL-C levels in the alirocumab group.
The treatment effect appeared numerically greater 
with lower HRs for patients with higher baseline LDL-C, 
suggesting that patients with a higher risk at baseline 
have a larger benefit of alirocumab. However, this linear 
trend was not statistically significant. Furthermore, be-
cause qualification for inclusion in the ODYSSEY OUT-
COMES trial required an ACS, patients with a history 
of cerebrovascular disease all had polyvascular disease, 
which is associated with a high risk of major adverse 
cardiovascular events and large absolute benefit of ali-
rocumab in reducing such events.13 Accordingly, stroke 
risk was markedly higher in patients with a history of 
Figure 1. Kaplan-Meier curves for any 
stroke, ischemic stroke and hemorrhagic 
stroke. 
CI indicates confidence interval; and HR, hazard 
ratio.
Figure 2. Stroke by history of cerebrovascu-
lar disease and baseline LDL-C category. 
LDL-C indicates low-density lipoprotein choles-
terol; and HR, hazard ratio.
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cerebrovascular disease, with a HR of 2.469 (95% CI, 
1.792–3.401) in multivariable analysis. However, the 
treatment effect of alirocumab on stroke was similar in 
both patients with or without a history of cerebrovascu-
lar disease. Therefore, alirocumab is a suitable therapy 
in patients with recent ACS, irrespective of baseline 
LDL-C and of history of cerebrovascular disease.
The potential association of very low LDL-C with 
hemorrhagic stroke risk has been investigated primar-
ily in epidemiologic studies,14 but more recently 2 large 
prospective cohort studies tried to provide clarity on 
this matter in healthy participants and found increased 
risks of hemorrhagic stroke with LDL-C <70 mg/dL.7,15 
The Women’s Health Study in the United States found 
an adjusted relative risk of 2.17 (95% CI, 1.05–4.48).15 
The Kailuan study in China reported adjusted HRs of 
1.65 (95% CI, 1.32–2.05) for LDL-C 50 to 69 mg/dL 
and 2.69 (95% CI, 2.03–3.57) for LDL-C <50 mg/dL.7 
Despite concerns regarding hemorrhagic stroke, our 
findings that intensive reduction of LDL-C did not cause 
harm in terms of hemorrhagic stroke reinforces and 
extends other previous data. The SPARCL trial (Stroke 
Prevention by Aggressive Reduction in Cholesterol Lev-
els) showed a reduction in overall strokes with high-
intensity atorvastatin therapy, despite a small increase 
in hemorrhagic stroke in 4731 patients with recent 
stroke or transient ischemic attack.16 SPARCL also dem-
onstrated that achieving ≥50% LDL-C lowering was as-
sociated with a greater reduction in the risk of ischemic 
stroke without increasing hemorrhagic stroke and that 
a higher risk of hemorrhagic stroke was largely in pa-
tients with a history of small vessel disease or nonath-
erothrombotic stroke.1,17
Similar conclusions regarding stroke were drawn 
from the FOURIER trial, investigating the PCSK9 in-
hibitor evolocumab added to statin therapy in 27 564 
patients with stable, established, atherosclerotic car-
diovascular disease, including 19.4% with a history of 
nonhemorrhagic stroke. Evolocumab treatment signif-
icantly reduced the risk of ischemic stroke (HR, 0.75 
[95% CI, 0.62–0.92]), without a significant effect on 
hemorrhagic stroke (HR, 1.16 [95% CI, 0.68–1.98]).10 
Although PCSK9 inhibition may lower LDL-C to levels 
far below those achieved with statins alone, FOURIER 
found that lower achieved LDL-C did not increase the 
risk of hemorrhagic stroke, even when LDL-C levels 
were <0.5 mmol/L (20 mg/dL).18
As most lipid trials have few hemorrhagic stroke 
events, a meta-analysis was performed recently of ran-
domized trials, including all lipid-lowering trials with 
statins, ezetimibe, and PCSK9 inhibition.9 The investi-
gators found a net benefit of lipid-lowering, with a rate 
ratio of 0.80 (95% CI, 0.76–0.84) for ischemic stroke 
and 1.17 (95% CI, 1.03–1.32) for hemorrhagic stroke, 
for each 1 mmol/L lower LDL-C achieved at about 1 
year of follow-up.9 Of note, in these studies different 
types and doses of lipid-lowering therapies were used 
in patients with or without proven vascular disease in 
various vascular beds, including coronary artery disease, 
peripheral artery disease, and cerebrovascular disease. 
Our results are in line with this meta-analysis in that 
we found a large benefit of alirocumab in multivariable 
analysis (HR, 0.712 [95% CI, 0.564–0.898]; P=0.0041) 
and no relationship between very low achieved LDL-
C and incidence of hemorrhagic stroke. However, 
given that only 33 patients had a hemorrhagic stroke, 
the confidence intervals were large, with an HR in all 
patients of 0.83 (95% CI, 0.42–1.65). The ongoing 
Treat  Stroke  to Target trial of patients with stroke of 
atherothrombotic origin treated with statins, is testing 
whether targeting a lower LDL-C level with statins and 
ezetimibe reduces cardiovascular event rates further, 
and will also provide additional prospective testing of 
the safety of that strategy.19
Table 2. Multivariable Model Predicting Stroke
Variable Hazard Ratio (95% CI) P Value
History of cerebrovascular disease 2.469 (1.792, 3.401) <0.0001
Glomerular filtration rate <60 mL/
min/1.73 m2
1.751 (1.328, 2.309) <0.0001
Age, per 1-year increment 1.027 (1.013, 1.042) 0.0001
History of diabetes 1.589 (1.251, 2.020) 0.0001
Systolic blood pressure, per 
1-mm Hg increment
1.012 (1.005, 1.019) 0.0008
LDL-C, per 1-mg/dL increment 1.005 (1.002, 1.008) 0.0009
Alirocumab treatment 0.712 (0.564, 0.898) 0.0041
History of heart failure 1.502 (1.124, 2.004) 0.0060
Geographic region
  Western Europe Reference 0.0065
  Eastern Europe 1.493 (1.010, 2.206)  
  North America 1.569 (1.032, 2.386)  
  South America 1.603 (1.013, 2.537)  
  Asia 2.288 (1.434, 3.648)  
  Rest of world 2.173 (1.371, 3.445)  
Myocardial infarction before index 
event
1.366 (1.056, 1.770) 0.0177
Specific oral anticoagulant 1.595 (1.054, 2.415) 0.0272
Current smoker 1.355 (1.024, 1.795) 0.0339
History of peripheral artery disease 1.497 (1.007, 2.223) 0.0461
HDL-C, per 1-mg/dL increment 0.989 (0.978, 1.000) 0.0476
Candidate predictors (stepwise selection), P=0.05 for entry or exit: age 
category, sex, race, geographic region, index event, lipid-lowering therapy 
at randomization, low-density lipoprotein cholesterol (LDL-C, HDL-C), 
lipoprotein(a), body mass index, systolic blood pressure, glomerular filtration 
rate, diabetes, hypertension, myocardial infarction, cerebrovascular disease, 
malignant disease, percutaneous coronary intervention, chronic obstructive 
pulmonary disease, coronary artery bypass graft, peripheral artery disease, 
congestive heart failure, venous thromboembolism, atrial fibrillation, current 
smoker, revascularization for index event, oral adenosine diphosphate receptor 
antagonist, oral anticoagulant, alirocumab treatment. HDL-C indicates high-
density lipoprotein cholesterol; and LCL-C, low-density lipoprotein cholesterol.
Jukema et al Effect of Alirocumab on Stroke After ACS















Median follow-up was relatively brief, at 2.8 years, and 
one cannot exclude that the effects of alirocumab on 
ischemic or particularly hemorrhagic stroke might dif-
fer with much longer-term follow-up. Therefore, a re-
lationship of alirocumab treatment to long-term risk of 
stroke is as yet unknown. A relatively small number of 
patients had a history of cerebrovascular disease, and 
therefore the power to detect effects of alirocumab in 
this subgroup was limited. Only a dedicated random-
ized controlled trial among individuals with cerebrovas-
cular disease could reliably establish the efficacy and 
safety in this subgroup. Because blood pressure was 
generally well controlled in the trial population, the 
present results may not necessarily apply in popula-
tions with uncontrolled blood pressure. In the analyses 
relating achieved LDL-C levels to subsequent risk of 
hemorrhagic stroke, patients who achieved lower LDL-
C might have other prognostic characteristics plac-
ing them at lower risk for this outcome, on average, 
relative to patients with higher achieved LDL-C. This, 
in combination with few hemorrhagic strokes after 
month 4, might in part explain the lack of an observed 
adverse relationship.
Conclusions
This analysis of the ODYSSEY OUTCOMES trial shows 
that in patients with recent ACS and dyslipidemia despite 
intensive statin therapy, the PCSK9 inhibitor alirocumab 
decreased the risk of stroke, irrespective of baseline LDL-C 
and of history of cerebrovascular disease, over a median 
follow-up of 2.8 years. Furthermore, the present findings 
indicate that the risk of hemorrhagic stroke did not de-
pend on achieved LDL-C levels in the alirocumab group.
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